US Patent 10202339 Therapeutic compounds and compositions
Patent 10202339 was granted and assigned to Agios Pharmaceuticals on February, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+561 characters)
Article
Patent abstract
Provided are aryl sulfonamide diarylurea derivative compounds that are inhibitors of mutant isocitrate dehydrogenase 1/2 (IDH 1/2), useful for treating cancer. Also provided are methods of treating cancer comprising administering to a subject in need thereof a compound described herein. Cancers that are treatable by the compounds of the invention are glioblastoma, myelodysplastic syndrome, myeloproliferative neoplasm, acute myelogenous leukemia, sarcoma, melanoma, non-small cell lung cancer, chondrosarcoma, and non-Hodgkin's lymphoma (NHL).
Edits on 19 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Apr, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102023390
Date of Patent
February 12, 2019
0Patent Application Number
144356740
Date Filed
October 11, 2013
0Patent Primary Examiner
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
102023390
Date of Patent
February 12, 2019
0Patent Application Number
144356740
Date Filed
October 11, 2013
0Patent Primary Examiner
Edits on 24 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10202339 Therapeutic compounds and compositions
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10202339
Date of patent
February 12, 2019
Patent application number
14435674
Date Filed
October 11, 2013
Patent primary examiner
Find more entities like US Patent 10202339 Therapeutic compounds and compositions
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.